SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 14,953 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $23.33, for a total value of $348,853.49. Following the completion of the transaction, the chief executive officer directly owned 353,176 shares of the company’s stock, valued at approximately $8,239,596.08. The trade was a 4.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Laura Francis also recently made the following trade(s):
- On Tuesday, November 17th, Laura Francis sold 1,901 shares of SiBone stock. The shares were sold at an average price of $23.18, for a total value of $44,065.18.
- On Wednesday, November 4th, Laura Francis sold 75,000 shares of SiBone stock. The stock was sold at an average price of $25.30, for a total transaction of $1,897,500.00.
- On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The stock was sold at an average price of $20.05, for a total transaction of $762,020.30.
- On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total transaction of $522,556.64.
- On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $78,538.46.
- On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.
SiBone Stock Up 1.6%
Shares of SiBone stock opened at $23.54 on Thursday. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.06 billion, a P/E ratio of -75.93 and a beta of 0.64. The firm’s 50 day moving average price is $20.67 and its 200-day moving average price is $16.89. SiBone has a 52-week low of $11.48 and a 52-week high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The company had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. On average, sell-side analysts predict that SiBone will post -0.34 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of SIBN. First Light Asset Management LLC lifted its holdings in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the period. Granahan Investment Management LLC increased its holdings in SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after buying an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY increased its holdings in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after buying an additional 598,300 shares during the period. Marshall Wace LLP raised its position in SiBone by 1.2% during the 3rd quarter. Marshall Wace LLP now owns 698,416 shares of the company’s stock worth $13,130,000 after buying an additional 8,128 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in SiBone by 9.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 483,029 shares of the company’s stock worth $9,081,000 after buying an additional 41,117 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.
Top SiBone Stories
Investors following SIBN have been watching these stories:
- Positive Sentiment: Sell-side brokerages reportedly rate SiBone a “Moderate Buy,” which may support investor sentiment. Article: SiBone Stock Rated Moderate Buy by Sell-Side Brokerages
- Neutral Sentiment: CEO Laura Francis and insiders Anshul Maheshwari and Michael Pisetsky sold a combined 26,959 shares on November 16–17, worth about $628,000. The reported sales covered tax withholding related to equity vesting; each insider retained a substantial stake, making the transactions less concerning than discretionary sales. CEO SEC filing Anshul Maheshwari SEC filing Michael Pisetsky SEC filing
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the company. Truist Financial upped their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. TD Cowen boosted their price target on SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a report on Wednesday. UBS Group upped their price objective on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Finally, Needham & Company LLC decreased their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, SiBone currently has an average rating of “Moderate Buy” and an average price target of $25.00.
Get Our Latest Stock Analysis on SIBN
About SiBone
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Further Reading
- Five stocks we like better than SiBone
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
